ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1824

Do Statins Reduce the Incidence of Connective Tissue Disease? A Retrospective Cohort Study

Thomas W. Schmidt1, Daniel F. Battafarano1, Christopher R. Frei2, Eric M. Mortensen3 and Ishak Mansi4, 1Rheumatology, San Antonio Military Medical Center, San Antonio, TX, 2Pharmacotherapy Education and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, 3Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, 4Internal Medicine, San Antonio Military Medical Center, San Antonio, TX

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Connective tissue diseases, Rheumatoid arthritis (RA), statins and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services Research: Rheumatic Disease Pharmacoepidemiology

Session Type: Abstract Submissions (ACR)

Background/Purpose: Due to their anti-inflammatory effects, statins were proposed to lower the incidence of connective tissue diseases (CTD). The objective of this study is to determine if statin use is associated with a lower incidence of CTD in a healthcare setting where patients have similar access to care.

Methods: This was a retrospective analysis of adult patients (30-85 year-old) enrolled as Tricare Prime in a military medical facility.  The study period was divided into baseline period (10/1/2003 to 9/30/2005), and follow up period (10/1/2005 to 3/5/2010). “Statin Users” received and dispensed a statin prescription of at least 90 days during the period from 10/1/2004 to 9/30/2005.  “Non-users” did not receive a statin at any time during the study period.  The outcome measure was the occurrence of any diagnosis code of the International Classification of Diseases, 9th Revision, Clinical Modification(ICD-9-CM) consistent with CTD (Rheumatoid arthritis and related disease, Systemic lupus erythematosus, and other connective tissue diseases as identified by the Clinical Classification Software of the Agency for Healthcare Research and Quality).  We described comorbidities during the baseline period using the Charlson comorbidity score (CCS). We repeated the analysis in a prespecified subgroup of patients with CCS of 0 (no comorbidities). 

Results: 46,488 patients were included: 13,640 statin-users and 32,848 non-users.  Statin users were predominately male (58.3% vs 43.8%), older (60.4 years vs 44.8 years), smokers (9.0% vs 5.8%) and had a higher average CCS (1.2 vs 0.3) (p<0.0001).  In the subgroup with no comorbidities, there were 6,137 statin users and 27,626 non-users. Regression analysis showed that statin users had a statistically significant lower incidence of connective tissue disease (adjusted odds ratio [OR]: 0.84; 95% confidence interval [CI]: 0.73 – 0.96; p-value=0.01). However, in the subgroup with no comorbidities, there was no difference between statin users and non-users in the incidence of CTD (adjusted OR: 0.83; 95% CI: 0.67 – 1.04; p-value=0.1).

Conclusion: Statin use is not associated with a lower incidence of CTD in patients without comorbidities. This finding may suggest that the beneficial effect of statins on CTD in many studies may be due to unadjusted baseline confounders or healthy user bias.


Disclosure:

T. W. Schmidt,
None;

D. F. Battafarano,
None;

C. R. Frei,
None;

E. M. Mortensen,
None;

I. Mansi,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/do-statins-reduce-the-incidence-of-connective-tissue-disease-a-retrospective-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology